TD Cowen analyst Phil Nadeau raised the firm’s price target on Vertex Pharmaceuticals to $360 from $350 and keeps an Outperform rating on the shares. Inaxaplin has produced strong POC in APOL-1 mediated focal segmental glomerulosclerosis and pivotal development is progressing in APOL1 mediated kidney disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals’ VX-880 showed treatment benefit, says BMO Capital
- Vertex Pharmaceuticals price target raised to $379 from $375 at Evercore ISI
- Vertex Pharmaceuticals and Lonza to build facility for T1D cell therapies
- Vertex Pharmaceuticals reports ‘positive’ Phase 1/2 VX-880 results
- Vertex announces FDA approval for KALYDECO to treat eligible infants with CF